Screener / SEC EDGAR /CIK 0001576280 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Guardant Health, Inc. GH

Compare with peers Embed
What it said it expected, against what it reported

2 targets with a reported result

Releases of the last 3 years
Above the range 2 above the last range given
Within the range 0 of 2 range targets
Below the range 0 below the last range given

The numbers GH said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Free cash flow (company-defined)
Fiscal 2026
Given $195.00M to $205.00M release Jul 30, 2026
Raised $205.00M to $220.00M release Nov 5, 2026
– No standard number
The company's words
Guardant Health now expects full-year free cash flow burn of $195 million to $205 million, compared with its previous outlook of $185 million to $195 million. release Jul 30, 2026
Guardant Health now expects full-year free cash flow burn of $205 million to $220 million, compared to the previous outlook of $195 million to $205 million. release Nov 5, 2026
Revenue
Fiscal 2026
Given $1.25B to $1.28B release Feb 19, 2026
Raised $1.30B to $1.32B release May 7, 2026
Raised $1.34B to $1.36B release Jul 30, 2026
Raised $1.36B to $1.37B release Nov 5, 2026
– Not reported yet
The company's words
Guardant Health expects full year 2026 revenue to be in the range of $1.25 to $1.28 billion, representing growth of 27% to 30% compared to full year 2025. release Feb 19, 2026
Raises 2026 revenue guidance to $1.30 to $1.32 billion, representing growth of 32% to 34% release May 7, 2026
Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38% release Jul 30, 2026
Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40% release Nov 5, 2026
Free cash flow (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $225.00M to $235.00M release Feb 20, 2025
– No standard number
The company's words
Guardant Health expects free cash flow burn to be in the range of $225 to $235 million in 2025, an improvement compared to $275 million for the full year 2024. release Feb 20, 2025
Revenue
Fiscal 2025 (ended Dec 31, 2025)
Given $850.00M to $860.00M release Feb 20, 2025
Raised $880.00M to $890.00M release Apr 30, 2025
Raised $915.00M to $925.00M release Jul 30, 2025
Raised $965.00M to $970.00M release Oct 29, 2025
$982.02M
10-K filed 2026-02-19
Above the range
The company's words
Expects full year 2025 total revenue to be in the range of $850 to $860 million release Feb 20, 2025
Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% release Apr 30, 2025
Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% release Jul 30, 2025
Raises 2025 revenue guidance to $965 to $970 million, representing year-over- year growth of 31% release Oct 29, 2025
Free cash flow (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $60.00M to $70.00M release Aug 7, 2024
Raised $70.00M to $80.00M release Nov 6, 2024
– No standard number
The company's words
Guardant Health continues to expect free cash flow to be in the range of $(275) to $(285) million in 2024, representing an improvement of $60 million to $70 million compared to 2023. release Aug 7, 2024
Revised annual free cash flow guidance to $(265) to $(275) million, an improvement of $70 to $80 million compared to 2023 release Nov 6, 2024
Revenue
Fiscal 2024 (ended Dec 31, 2024)
Given $655.00M to $670.00M release Feb 22, 2024
Raised $675.00M to $685.00M release May 9, 2024
Raised $690.00M to $700.00M release Aug 7, 2024
Raised $720.00M to $725.00M release Nov 6, 2024
$739.02M
10-K filed 2026-02-19
Above the range
The company's words
Expects full year 2024 revenue to be in the range of $655 to $670 million release Feb 22, 2024
Raised 2024 annual guidance for revenue to a new range of $675 to $685 million, representing growth of 20% to 21% release May 9, 2024
Raised 2024 annual guidance for revenue to a new range of $690 to $700 million, representing growth of 22% to 24% release Aug 7, 2024
Raised 2024 annual guidance for revenue to a new range of $720 to $725 million, representing growth of 28% to 29% release Nov 6, 2024
Revenue (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $655.00M to $670.00M release Feb 22, 2024
Raised $675.00M to $685.00M release May 9, 2024
Raised $690.00M to $700.00M release Aug 7, 2024
– No standard number
The company's words
Guardant Health expects full year 2024 revenue excluding screening to be in the range of $655 to $670 million, representing growth of 16% to 19% compared to full year 2023, and full year 2024 non-GAAP gross margin excluding screening to be in the range of 60% to 62%. release Feb 22, 2024
Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023 This compares to the prior range of $655 to $670 million, representing growth of 16% to 19%. release May 9, 2024
Guardant Health now expects full year 2024 revenue excluding screening to be in the range of $690 to $700 million, representing growth of 22% to 24% compared to full year 2023 This compares to the prior range of $675 to $685 million, representing growth of 20% to 21%. release Aug 7, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (15 releases since 2024-01-08), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GH/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.